Abstract：
BACKGROUND: While electrochemotherapy (ECT) is increasingly utilized as a highly effective method in the treatment of tumors in the head and neck region, there is significantly less data available for eyelid-periocular skin tumors. Our group reported the first extensive case series of eyelid-periocular basal cell carcinoma (BCC) patients with short-term follow-up treatment with ECT. The present study aims to report our long-term results of eyelid-periocular BCC cases treated with ECT.
METHODS: The treatments were performed according to the ESOPE (European Standard Operating Procedures on Electrochemotherapy) guidelines using the Cliniporator™ device. All patients received bleomycin-based ECT, administered intratumorally or intravenously. Tumor response was evaluated using the RECIST 1.1 criteria.
RESULTS: The results of 19 patients treated with ECT are presented. Four patients had locally advanced primary tumors, while 15 patients had recurrent tumors. Bleomycin was administered intratumorally in four patients and intravenously in 15 patients. The overall response was 100%, while the complete response rate proved to be 95%. In three cases (15.8%), recurrence was observed during the mean follow-up period of 78.9 months.
CONCLUSIONS: ECT can effectively treat locally advanced or recurrent BCC in the eyelid-periocular skin region. Excellent tumor control can be achieved with good functional and cosmetic results without systemic adverse events with long interval follow-up.
METHODS: The treatments were performed according to the ESOPE (European Standard Operating Procedures on Electrochemotherapy) guidelines using the Cliniporator™ device. All patients received bleomycin-based ECT, administered intratumorally or intravenously. Tumor response was evaluated using the RECIST 1.1 criteria.
RESULTS: The results of 19 patients treated with ECT are presented. Four patients had locally advanced primary tumors, while 15 patients had recurrent tumors. Bleomycin was administered intratumorally in four patients and intravenously in 15 patients. The overall response was 100%, while the complete response rate proved to be 95%. In three cases (15.8%), recurrence was observed during the mean follow-up period of 78.9 months.
CONCLUSIONS: ECT can effectively treat locally advanced or recurrent BCC in the eyelid-periocular skin region. Excellent tumor control can be achieved with good functional and cosmetic results without systemic adverse events with long interval follow-up.
摘要：
背景：虽然电化学疗法（ECT）越来越多地用作治疗头颈部肿瘤的高效方法，眼睑-眼周皮肤肿瘤的可用数据明显较少.我们小组报告了第一例广泛的眼睑眼周基底细胞癌（BCC）患者，并接受了ECT的短期随访治疗。本研究旨在报告我们接受ECT治疗的眼睑眼周BCC病例的长期结果。
方法:根据ESOPE(关于电化学化学疗法的欧洲标准操作规程)指南使用Cliniporator™装置进行治疗。所有患者都接受了基于博来霉素的ECT，瘤内或静脉内给药。使用RECIST1.1标准评价肿瘤反应。
结果：介绍了用ECT治疗的19例患者的结果。四名患者患有局部晚期原发性肿瘤，15例患者肿瘤复发。博来霉素在4例患者中进行了瘤内给药，在15例患者中进行了静脉内给药。总体反应是100%,而完全缓解率为95%。在三个案例中（15.8%），在平均78.9个月的随访期间观察到复发.
结论：ECT可有效治疗眼睑-眼周皮肤区域的局部晚期或复发性BCC。具有良好的功能和美容效果，可以实现出色的肿瘤控制，而不会出现全身性不良事件，并进行长时间的随访。
方法:根据ESOPE(关于电化学化学疗法的欧洲标准操作规程)指南使用Cliniporator™装置进行治疗。所有患者都接受了基于博来霉素的ECT，瘤内或静脉内给药。使用RECIST1.1标准评价肿瘤反应。
结果：介绍了用ECT治疗的19例患者的结果。四名患者患有局部晚期原发性肿瘤，15例患者肿瘤复发。博来霉素在4例患者中进行了瘤内给药，在15例患者中进行了静脉内给药。总体反应是100%,而完全缓解率为95%。在三个案例中（15.8%），在平均78.9个月的随访期间观察到复发.
结论：ECT可有效治疗眼睑-眼周皮肤区域的局部晚期或复发性BCC。具有良好的功能和美容效果，可以实现出色的肿瘤控制，而不会出现全身性不良事件，并进行长时间的随访。
